FoldRx touts tafamidis data

FoldRx Pharmaceuticals announced that the Phase II/III study for tafamidis demonstrates that the drug "significantly halts disease progression for patients with a disease called Transthyretin-TTR--amyloid polyneuropathy." FoldRx co-founder Jeffery Kelly, Ph.D., said that "this is the first pharmacologic evidence that the biomedical researcher communities' hypothesis about the etiology of human amyloid diseases, including Alzheimer's disease, is likely correct. The development of tafamidis--the first disease-modifying agent targeting the underlying cause of a human amyloid disease--was built on years of basic scientific research, funded by institutions including the National Institutes of Health, the Skaggs Institute for Chemical Biology, and The Lita Annenberg Hazen Foundation." Release

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.